Graft options for ACL reconstruction include: •
Autografts (employing bone or tissue harvested from the patient's body). •
Allografts (using bone or tissue from another body, either a
cadaver or a live donor). • Bridge-enhanced ACL repair (using a bio-engineered bridging scaffold injected with the patient's own blood). • Synthetic tissue for ACL reconstruction has also been developed, but little data exists on its strength and reliability.
Autograft An accessory
hamstring or part of the
patellar ligament are the most common donor tissues used in autografts. While originally less commonly utilized, the
quadriceps tendon has become a more popular graft. Because the tissue used in an autograft is the patient's own, the risk of
rejection is minimal. The retear rate in young, active individuals has been shown to be lower when using autograft as compared to allograft. No fully ideal autograft site for ACL reconstruction exists. Surgeons have historically regarded patellar tendon grafts as the "gold standard" for knee stability. Hamstring grafts historically had problems with fixation slippage and stretching out over time. Modern fixation methods avoid graft slippage and produce similarly stable outcomes with easier rehabilitation, less anterior knee pain and less joint stiffness. The quadriceps tendon, while historically reserved for revision reconstructions, has enjoyed a renewed focus as a versatile and durable graft for primary reconstructions. Use of the quadriceps tendon usually does not result in the same degree of anterior knee pain postoperatively, and quadriceps tendon harvest produces a reliably thick, robust graft. The quadriceps tendon has approximately 20% greater collagen per cross-sectional area than the patellar tendon, and a greater diameter of usable soft tissue is available.
Hamstring tendon and
medial meniscus repair. "Socks" are actually post-op pressure stockings. Hamstring autografts are made with the
semitendinosus tendon, either alone or accompanied by the
gracilis tendon for a stronger graft. The semitendinosus is an accessory hamstring (the primary hamstrings are left intact), and the gracilis is not a hamstring, but an accessory adductor (the primary adductors are left intact as well). The two tendons are commonly combined and referred to as a four-strand hamstring graft, made by a long piece (about 25 cm) removed from each tendon. The tendon segments are folded and braided together to form a tendon of quadruple thickness for the graft. The braided segment is threaded through the heads of the
tibia and
femur, and its ends are fixed with screws on the opposite sides of the two bones. Unlike the patellar ligament, the hamstring tendon's fixation to the bone can be affected by motion after surgery. Therefore, a brace is often used to immobilize the knee for one to two weeks. Evidence suggests that the hamstring tendon graft does as well, or nearly as well, as the patellar ligament graft in the long term. A Cochrane review in 2011 found insufficient evidence to suggest whether a hamstring versus patellar ligament graft was superior. It found that individuals receiving hamstring autografts had reduced flexion (bending knee) range of motion and strength. Saphenous Nerve Injury prevention during Hamstring tendon harvesting is achieved primarily through careful incision planning and meticulous surgical technique. Oblique or modified oblique skin incisions are preferred over vertical or transverse incisions to minimize the risk of injuring the infrapatellar branch of the saphenous nerve. Limited soft-tissue dissection and delicate handling of the subcutaneous layer are essential to preserve small sensory branches. Direct visualization and protection of the nerve may be performed when its course is identifiable. The use of posterior or popliteal incisions, as well as minimally invasive or endoscopic harvesting techniques, has been shown to further decrease the incidence of iatrogenic nerve damage. There is some controversy as to how well a hamstring tendon regenerates after the harvesting. Most studies suggest that the tendon can be regenerated at least partially, though it will still be weaker than the original tendon. Advantages of hamstring grafts include their high "load to failure" strength, the stiffness of the graft, and the low postoperative morbidity. The natural ACL can withstand a load of up to 2,160
newtons. With a hamstring graft, this number doubles, decreasing the risk of re-injury. The stiffness of a hamstring graft—quadruple that of the natural ACL (Bartlett, Clatworthy and Ngugen, 2001)—also reduces the risk of re-injury.
Patellar tendon The patellar tendon connects the
patella (kneecap) to the tibia (shin). The graft is normally taken from the injured knee, but in some circumstances, such as a second operation, the other knee may be used. The middle third of the tendon is used, with bone fragments removed on each end. The graft is then threaded through holes drilled in the tibia and femur, and screwed into place. It is slightly larger than a hamstring graft. A 2011 Cochrane review, found no significant difference in long term outcome between patellar and hamstring autografts. Some or all of these disadvantages may be attributable to post-operative patellar tendon shortening. The
rehabilitation after the surgery is different for each knee. The beginning rehab for the ACL graft knee is focused on reducing
swelling, gaining full
range of motion, and stimulating the leg muscles. The goal for the
graft donor need is to immediately start
high repetition strength training exercises.
Allograft The patellar ligament,
tibialis anterior tendon, or
Achilles tendon may be recovered from a cadaver and used in ACL reconstruction. The Achilles tendon, because of its large size, must be shaved to fit within the joint cavity. Although there is less experience with the use of
tibialis anterior grafts, preliminary data has shown no difference in short-term subjective outcomes between tibialis anterior allografts and patellar tendon allografts.
Bridge Enhanced ACL Restoration (BEAR Implant) In addition to traditional ACL reconstruction, alternative surgical approaches have been developed that aim to preserve and heal the patient’s native ACL rather than replacing it with a tendon graft. One such technique is Bridge-Enhanced ACL Restoration (BEAR), which uses a collagen implant placed between the torn ends of the ligament to facilitate healing. During the procedure, the implant is saturated with a small amount of the patient’s blood and secured with sutures to bridge the gap between the torn ligament ends. This creates a protected environment that supports healing of the native ligament. In contrast to ACL reconstruction, which replaces the torn ligament with autograft or allograft tissue, the BEAR procedure aims to restore the patient’s original ligament structure. The technique was developed through research at Boston Children’s Hospital and Harvard Medical School investigating biological approaches to stimulate ACL healing. Much of the early research leading to the development of the BEAR technique was conducted by orthopedic surgeon and researcher Martha M. Murray, whose work focused on understanding why the ACL does not heal naturally and how biological scaffolds might enable ligament regeneration. The implant used in the procedure is manufactured by Miach Orthopaedics, a medical device company focused on facilitating connective tissue restoration. Early clinical studies comparing BEAR with autograft ACL reconstruction reported comparable outcomes in knee stability and patient-reported function at two-year follow-up, with improved hamstring strength observed in some patients treated with the BEAR procedure. Additional clinical research is ongoing. The BEAR-MOON study, a multicenter clinical trial evaluating outcomes following BEAR, has completed patient enrollment and is continuing long-term follow-up. Miach Orthopaedics is also conducting additional studies, including the BEAR III trial and the Bridge Registry, to evaluate clinical outcomes and longer-term joint health following ACL repair using the BEAR technique. The BEAR Implant received authorization from the U.S. Food and Drug Administration (FDA) in 2020 through the De Novo classification pathway for use in patients 14+ with a complete ACL tear. In 2025, the FDA cleared an expanded indication for use, allowing the implant to be used in a broader group of patients (ages 2+ , as well as those with partial tears) based on additional clinical evidence. In 2026, the FDA approved an updated label indicating a significantly lower observed risk of post-traumatic osteoarthritis in patients treated with the BEAR Implant compared with ACL reconstruction in clinical studies. Studies have reported similar rates of return to sport following BEAR and ACL reconstruction in appropriately selected patients.
Choice of graft type Typically, age and lifestyle help determine the type of graft used for ACL reconstruction. Bone-patellar tendon-bone grafts have resulted fewer failures and more stability on KT-1000 arthrometer testing. == Surgical technique ==